

The Dale Schenk Alzheimer's Association Research Roundtable Grant Award



May 10, 1957 – September 30, 2016

The Research Roundtable sponsors Alzheimer's Association grants. The chosen project is named The Dale Schenk Alzheimer's Association Research Roundtable Grant and the principal investigator of the project is invited to give a progress report at a Roundtable meeting.

This award is named in honor of the late Dr. Dale Schenk, who was the CEO of Prothena Corporation at the time of his death. Dr. Schenk was a founding member and the first Chair of the Research Roundtable serving from 2004 to 2010. His vision and leadership helped to bring the Research Roundtable into existence with just 4 member companies in 2004 to today with approximately 25 member companies.

Dr. Schenk was a recognized leader in Alzheimer's research. His career included many important breakthroughs including the immunization of PDAPP transgenic mice with an A β vaccine that reduced the accumulation of amyloid plaques in their brains (Schenk, et. al. Nature, 1999) and the discovery and development of AN1792, the first immunotherapy against A β to enter clinical trials.

The Alzheimer's Association is indebted to Dale for his leadership and commitment to Alzheimer's disease and hopes that the researchers that receive this award will emulate the standard of scientific excellence that Dr. Schenk established throughout his career.